TY - JOUR
T1 - Adjuvant therapy for neuroendocrine small cell carcinoma of the cervix
T2 - Review of the literature
AU - O'Hanlan, Katherine A.
AU - Goldberg, Gary L.
AU - Jones, Joan G.
AU - Runowicz, Carolyn D.
AU - Ehrlich, Laurence
AU - Rodriguez-Rodriguez, Lorna
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1991/11
Y1 - 1991/11
N2 - Neuroendocrine cell carcinoma of the cervix is a virulent tumor associated with an extremely poor prognosis. Even in clinical Stage I disease, there may be subclinical hematogenous and lymphatic metastases with frequent recurrences. Adjuvant postoperative external pelvic radiotherapy has been reported to offer some degree of local control; however, most patients succumb to distant disease. Following radical abdominal hysterectomy and pelvic lymphadenectomy, with confirmation of the neuroendocrine tumor by electron microscopy and immunohistochemical staining, two patients were given adjuvant systemic chemotherapy with concurrent pelvic radiotherapy, employing regimens with documented activity against small cell carcinoma of the lung of neuroendocrine origin. Despite severe myelotoxicity and persistent neuropathy, both patients are alive without clinical evidence of disease at 28+ and 47+ months.
AB - Neuroendocrine cell carcinoma of the cervix is a virulent tumor associated with an extremely poor prognosis. Even in clinical Stage I disease, there may be subclinical hematogenous and lymphatic metastases with frequent recurrences. Adjuvant postoperative external pelvic radiotherapy has been reported to offer some degree of local control; however, most patients succumb to distant disease. Following radical abdominal hysterectomy and pelvic lymphadenectomy, with confirmation of the neuroendocrine tumor by electron microscopy and immunohistochemical staining, two patients were given adjuvant systemic chemotherapy with concurrent pelvic radiotherapy, employing regimens with documented activity against small cell carcinoma of the lung of neuroendocrine origin. Despite severe myelotoxicity and persistent neuropathy, both patients are alive without clinical evidence of disease at 28+ and 47+ months.
UR - http://www.scopus.com/inward/record.url?scp=0026354318&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026354318&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(91)90066-E
DO - 10.1016/0090-8258(91)90066-E
M3 - Article
C2 - 1660433
AN - SCOPUS:0026354318
SN - 0090-8258
VL - 43
SP - 167
EP - 172
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 2
ER -